The Antimalignin Antibody in Serum (AMAS) Test is 97% sensitive in predicting which small breast masses or lesions on mammography would be found to be malignant on subsequent biopsy.
The AMAS Test is being used in the U.S. and abroad as an aid to the early detection of cancer. Since the test indicates whether active cancer cells are present in the body but does not tell their location, it is used together with other clinical procedures and tests which suggest where the lesion is located.
AMAS is also used with the PSA , CA125 and CAT scans. In studies, the AMAS elevation often precedes PSA or CA125 elevation by weeks or months.
In patients who have recently, or in past years, had cancer treated, the AMAS Test is also being used to monitor for remission or recurrence. As shown in a study of 8,090 patients and controls, this use for monitoring is as accurate as that for early detection.
Doctors also order the AMAS Test for individuals who have never had cancer but are at a higher risk. In individuals where the family history indicates an earlier onset of cancer, AMAS testing has been ordered routinely in the 30’s or 40’s.
